首页> 外文学位 >Genetic testing for sale: Implications of commercial BRCA testing in Canada.
【24h】

Genetic testing for sale: Implications of commercial BRCA testing in Canada.

机译:待售的基因测试:在加拿大进行商业性BRCA测试的含义。

获取原文
获取原文并翻译 | 示例

摘要

Ongoing research in the fields of genetics and biotechnology hold the promise of improved diagnosis and treatment of genetic diseases, and potentially the development of individually tailored pharmaceuticals and gene therapies. Difficulty, however, arises in determining how these services are to be evaluated and integrated equitably into public health care systems such as Canada's. The current context is one of increasing fiscal restraint on the part of governments, limited financial resources being dedicated to health care, and rising costs for new health care services and technologies. This has led to increasing public debate in the last few years about how to reform public health care, and whether we should prohibit, permit or perhaps even encourage private purchase of health care services.; In Canada, some of these concerns have crystallized around the issue of gene patents and commercial genetic testing, in particular as illustrated by the case of Myriad Genetics' patented BRACAnalysis test for hereditary breast and ovarian cancer. While most Canadians who currently access genetic services do so through the public health care system, for those with the means, private purchase is becoming an option. This situation raises serious concerns—about justice in access to health care; about continued access to safe and reliable genetic testing supported by unbiased patient information; and about the broader effects of commercialization for ongoing research and the Canadian public health care system. Commercial genetic testing presents a challenge to health care professionals, policy analysts, and academics concerned with the social, ethical and policy implications of new genetic technologies. Using the Myriad case as an exemplar, tools from moral philosophy, the social sciences, and health policy and law will be brought to bear on the larger issues of how as a society we should regulate commercial research and product development, and more coherently decide which services to cover under public health insurance and which to leave to private purchase. Generally, the thesis is concerned with the question of “how best to bring capital, morality, and knowledge into a productive and ethical relationship” (Rabinow 1999, 20).
机译:正在进行的遗传学和生物技术领域的研究有望改善遗传疾病的诊断和治疗,并有可能开发个性化的药物和基因疗法。但是,在确定如何评估这些服务并将其公平地整合到加拿大等公共卫生保健系统中时出现了困难。当前的情况是政府方面日益增加的财政约束,用于医疗保健的财政资源有限以及新医疗保健服务和技术的成本不断上升。这导致最近几年公众对如何改革公共卫生保健以及我们是否应该禁止,允许甚至鼓励私人购买卫生保健服务进行辩论。在加拿大,围绕基因专利和商业基因检测的问题已经引起了一些关注,特别是如Myriad Genetics针对遗传性乳腺癌和卵巢癌获得专利的 BRACAnalysis 测试所证明的那样。尽管大多数目前使用基因服务的加拿大人是通过公共卫生保健系统这样做的,但对于那些有能力的人来说,私人购买已成为一种选择。这种情况引起了人们的严重关切,即在获得医疗保健方面的正义。在无偏见的患者信息的支持下继续获得安全可靠的基因检测的方法;以及商业化对正在进行的研究和加拿大公共卫生保健系统的广泛影响。商业基因测试给关心新基因技术的社会,道德和政策影响的医疗保健专业人员,政策分析人员和学者带来了挑战。以无数案为例,道德哲学,社会科学以及卫生政策和法律的工具将被带到更大的问题上,即我们作为一个社会应如何规范商业研究和产品开发,并更连贯地决定服务覆盖公共健康保险,由私人购买。一般而言,本文的主题是“如何最佳地将资本,道德和知识带入生产性和道德关系”(Rabinow 1999,20)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号